Focus Area Program
Duchenne Muscular Dystrophy (DMD)
Not SpecifiedCore Focus Area
Key Facts
Indication
Duchenne Muscular Dystrophy (DMD)
Phase
Not Specified
Status
Core Focus Area
Company
About Santhera Pharmaceuticals
Santhera Pharmaceuticals is a Swiss public company with a focused mission to develop and commercialize treatments for rare neuromuscular diseases, exemplified by its long-term dedication to Duchenne muscular dystrophy (DMD). The company's strategy centers on identifying and advancing compounds that address specific pathological mechanisms in these high-need areas. While historically involved with the FDA-approved drug vamorolone for DMD, Santhera's current pipeline and strategic direction emphasize its ongoing commitment to this challenging therapeutic space.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy (DMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DT-DEC01 | Dystrogen Therapeutics | Phase 1 |
| Skeletal Muscle Regeneration Program | IPS HEART | Pre-clinical |
| KYMBEE (deflazacort) | Upsher-Smith | Approved |
| ALY688ER | Allysta Pharmaceuticals | Phase 1 |
| AVGN7 + AVGND | AAVogen | Pre-clinical |
| Myomatrix Stabilization Program | Strykagen | Preclinical |
| RIPPLE™ (implied) | SonoThera | Preclinical |
| Vamorolone (AGAMREE) | ReveraGen BioPharma | Approved |
| RGX-202 | ReGenX Biosciences | Phase 1/2 |
| AGAMREE (vamorolone) | Catalyst Pharmaceuticals | Marketed |
| EDG-5506 | Edgewise Therapeutics | Phase 2 |
| ELEVIDYS (delandistrogene moxeparvovec-rokl) | Sarepta Therapeutics | Marketed / Phase 3 |